NeuroVive signs mitochondrial medicine research agreement with US key opinion leader
GenSight Biologics reports sustained visual acuity gain at 78 weeks in its Phase I/II Study with GS010 for the treatment of Leber’s Hereditary Optic Neuropathy (LHON)
Khondrion announces completion of patient recruitment and first-in-patient dosing in its KHENERGY study, a phase 2 clinical trial with KH176 in MELAS/MIDD and mixed mitochondrial syndromes
Stealth BioTherapeutics Initiates Phase 2 Study of Elamipretide which will evaluate the long-term safety, tolerability and efficacy
Khondrion initiates the KHENERGY study, a phase 2 clinical trial of KH176 in MELAS/MIDD and mixed mitochondrial syndromes
GenSight Biologics receives approval to include teenage patients in RESCUE and REVERSE Phase III trials with GS010 in Leber’s Hereditary Optic Neuropathy
Edison Pharmaceuticals Announces Positive Results from Phase 2 Placebo-Controlled EPI- 743 Leigh Syndrome Trial
Stealth BioTherapeutics Reports Positive Elamipretide Data in First-Of-Its-Kind Primary Mitochondrial Myopathy Trial
GenSight Biologics announces additional promising results of its Phase I/II study with GS010 for the treatment of Leber’s Hereditary Optic Neuropathy (LHON)
Stealth BioTherapeutics Reports Positive Results for Primary Mitochondrial Myopathy Trial
Clinical Investigations of Mitochondrial Replacement Techniques Are ‘Ethically Permissible’ If Significant Conditions Are Met.
A Comprehensive Genomic Analysis Reveals the Genetic Landscape of Mitochondrial Respiratory Chain Complex Deficiencies.
Stealth BioTherapeutics Receives FDA Fast Track Designation for Rare Disease Indication.
Khondrion reports successful outcome of KH176 Phase 1 Clinical trials.
Mitochonic Acid 5 Binds Mitochondria and Ameliorates Renal Tubular and Cardiac Myocyte Damage.
Santhera launches Raxone® in its first EU market.
GenSight Biologics Receives IND Acceptance from FDA to Enter Phase III with GS010.
Reata Enrolls First Patient in the MOTOR Study, a Phase 2 Study of the Safety, Efficacy, and Pharmacodynamics of RTA 408 in the Treatment of Mitochondrial Myopathies.
【Clinical Trial Update】Raxone® (idebenone) for LHON
Santhera Pharmaceuticals (SIX: SANN) announces that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended granting a marketing authorization for Raxone® (idebenone) for the treatment of visual impairment in adolescent and adult patients with LHON.
Epigenetic regulation of the nuclear-coded GCAT and SHMT2 genes confers human age-associated mitochondrial respiration defects